BlackRock
DICE

BlackRock’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

BlackRock’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,895,307
Closed -$135M – 5603
2023
Q2 		$135M Sell
2,895,307
-117,134
-4% -$4.05M ﹤0.01% 1848
2023
Q1 		$86.3M Sell
3,012,441
-39,661
-1% -$1.17M ﹤0.01% 2100
2022
Q4 		$95.2M Buy
3,052,102
+1,145,411
+60% +$37.4M ﹤0.01% 2029
2022
Q3 		$38.7M Buy
1,906,691
+187,979
+11% +$3.43M ﹤0.01% 2646
2022
Q2 		$26.7M Buy
1,718,712
+858,172
+100% +$14.8M ﹤0.01% 2924
2022
Q1 		$16.5M Buy
860,540
+5,245
+0.6% +$93.6K ﹤0.01% 3297
2021
Q4 		$21.6M Buy
+855,295
New +$25.1M ﹤0.01% 3225

BlackRock's DICE Position: Q3 2023 in Review

BlackRock sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 2,895,307 shares — an estimated $135M sold.

BlackRock first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $135M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • BlackRock reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • BlackRock sold 2,895,307 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $135M.
  • BlackRock first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • BlackRock's DICE Therapeutics, Inc. Common Stock position peaked at $135M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.